This posttreatment section has been especially prepared for those individuals with cancer who have been off all antineoplastic therapy for at least 6 months. The rationale for creating a separate section is twofold. First, the etiology of problems is different for individuals receiving treatment versus those who are no longer receiving therapy. Second, intervention strategies and information can be better tailored so that there will be a greater likelihood of meeting the needs of these two distinct populations.
Fatigue is a separate and distinct problem for individuals after treatment is completed. Many theories have been proposed to explain the etiology of fatigue in the patient undergoing treatment and to explain the impact of that treatment on quality of life. Many of these theories, however, do not apply to the posttreatment population. Nonetheless, fatigue continues to be a major issue for individuals who are no longer receiving therapy and who are considered to be disease free.
Clinical validity refers to the predictive value of a test for a given clinical outcome (e.g., the likelihood that cancer will develop in someone with a positive test). It is primarily determined by the sensitivity and specificity with which a test identifies people with a defined clinical condition within a given population. Sensitivity of a test refers to the proportion of people who test positive for a clinical condition among those who actually have the clinical condition; specificity refers...
There is evidence that fatigue significantly affects the quality of life of cancer survivors. The experience of fatigue in cancer survivors is quite similar to the experience of patients with chronic fatigue syndrome in the general medical setting. Few studies have been done that indicate the impact of fatigue on quality of life, but some examples follow:
In cancer survivors who had bone marrow transplants, 50% of 29 survivors reported moderate-to-severe fatigue more than 1 year after transplant. Fatigue was one of the three most negative items studied and had an impact on quality of life more than any other physical problem.
In patients who had bone marrow transplants, 56% of 125 patients reported ongoing fatigue 6 to 18 years after transplant.
Of 687 posttreatment survivors of various forms of cancer evaluated for quality-of-life issues, fatigue was one of the three most negative items affecting quality of life.
Of 90 patients with a diagnosis of Hodgkin lymphoma or non-Hodgkin lymphoma, 30 reported a lack of energy at a median of 32 months after diagnosis.
Of 403 individuals with Hodgkin lymphoma, 37% reported their energy levels had not returned to levels that satisfied them even after a median of 9 years posttreatment.
In Hodgkin lymphoma survivors, 26% had persistent fatigue 6 months after treatment with 50% associated with psychological distress. Increasing age and no prior psychological symptoms predicted fatigue "caseness."
Of 162 women treated with radiation for breast cancer and 173 women treated with chemotherapy for breast cancer, 75% and 61%, respectively, described decreased stamina 2 to 10 years after the completion of treatment. In a separate cross-sectional survey of women who completed therapy for breast cancer by a mean of 29 months prior to the survey, 38% had severe fatigue compared with only 11% of matched controls.
Fatigue has been reported in women survivors of autologous bone marrow transplantation and high-dose chemotherapy treatment for lymphomas 4 to 10 years posttreatment.
Almost one-third of breast cancer survivors at 10 years posttreatment reported significant fatigue.